These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 33663537

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
    Ishimura A, Watanabe M, Nakashima H, Ito K, Miyake K, Mochizuki S, Ishigaki Y, Saito T.
    Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
    Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT.
    J Biol Chem; 2000 Oct 06; 275(40):31269-73. PubMed ID: 10903326
    [Abstract] [Full Text] [Related]

  • 5. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
    Toyota K, Hashimoto T, Ogino D, Matsunaga A, Ito M, Masakane I, Degawa N, Sato H, Shirai S, Umetsu K, Tamiya G, Saito T, Hayasaka K.
    J Hum Genet; 2013 May 06; 58(5):254-8. PubMed ID: 23407349
    [Abstract] [Full Text] [Related]

  • 6. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
    Saito T, Matsunaga A, Oikawa S.
    Am J Kidney Dis; 2006 Feb 06; 47(2):199-211. PubMed ID: 16431249
    [Abstract] [Full Text] [Related]

  • 7. Topics in lipoprotein glomerulopathy: an overview.
    Saito T, Matsunaga A, Ito K, Nakashima H.
    Clin Exp Nephrol; 2014 Apr 06; 18(2):214-7. PubMed ID: 24149835
    [Abstract] [Full Text] [Related]

  • 8. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W.
    J Am Soc Nephrol; 2001 Mar 06; 12(3):524-530. PubMed ID: 11181800
    [Abstract] [Full Text] [Related]

  • 9. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
    da Silveira-Neto JN, de Oliveira Ahn GJ, de Menezes Neves PDM, Baptista VAF, de Almeida Araújo S, Wanderley DC, Watanabe A, Watanabe EH, Murai NM, Bertollo EMG, Vieira-Neto OM, Dantas M, de Antônio SR, Costa RS, Baptista MASF, Moysés-Neto M, Onuchic LF.
    Diagn Pathol; 2021 Jul 26; 16(1):65. PubMed ID: 34311745
    [Abstract] [Full Text] [Related]

  • 10. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J.
    Kidney Int Suppl; 1999 Jul 26; 71():S37-41. PubMed ID: 10412734
    [Abstract] [Full Text] [Related]

  • 11. A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.
    Wang R, Zhao C, Chen W, Liu Z, Xie F.
    J Med Case Rep; 2022 Feb 23; 16(1):78. PubMed ID: 35193676
    [Abstract] [Full Text] [Related]

  • 12. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
    Yang M, Weng Q, Pan X, Hussain HMJ, Yu S, Xu J, Yu X, Liu Y, Jin Y, Zhang C, Li X, Ren H, Chen N, Xie J.
    Mol Genet Genomic Med; 2020 Aug 23; 8(8):e1281. PubMed ID: 32441489
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
    Bomback AS, Song H, D'Agati VD, Cohen SD, Neal A, Appel GB, Rovin BH.
    Nephrol Dial Transplant; 2010 Oct 23; 25(10):3442-6. PubMed ID: 20624773
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.
    Qin Y, Sun XJ, Hu YF, Jing M, Yu XJ, Zhao MH, Tan Y.
    Ren Fail; 2024 Dec 23; 46(1):2332491. PubMed ID: 38584145
    [Abstract] [Full Text] [Related]

  • 17. Lipoprotein glomerulopathy in China.
    Chen Y.
    Clin Exp Nephrol; 2014 Apr 23; 18(2):218-9. PubMed ID: 24165683
    [Abstract] [Full Text] [Related]

  • 18. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
    Zhang B, Liu ZH, Zeng CH, Zheng JM, Chen HP, Zhou H, Li LS.
    Chin Med J (Engl); 2005 Apr 05; 118(7):555-60. PubMed ID: 15820086
    [Abstract] [Full Text] [Related]

  • 19. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.
    Tavori H, Fan D, Giunzioni I, Zhu L, Linton MF, Fogo AB, Fazio S.
    J Lipid Res; 2014 Oct 05; 55(10):2073-81. PubMed ID: 25183802
    [Abstract] [Full Text] [Related]

  • 20. Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.
    Cambruzzi E, Pêgas KL.
    J Bras Nefrol; 2019 Oct 05; 41(3):393-399. PubMed ID: 30421781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.